Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Pfizer
ImmunoGen, Inc.
National Cheng-Kung University Hospital
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center